MOA

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

Retrieved on: 
Monday, April 8, 2024
PARP1, Chem, MDA, Drug, Patient, Cancer, IND, Abstract, AACR, Survivor, DRF, Clinical trial, PARP, MOA, Xenotransplantation, Safety, Biology, San Diego Convention Center, Drug discovery, Medicine, Annual general meeting, PCC, Pharmaceutical industry

"After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.

Key Points: 
  • "After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.
  • Laekna will continue our internal effort of discovery novel drug candidates to provide more options for patients."
  • The company has internally discovered 14 drug candidates, among which seven have been optimized and advanced to PCC (pre-clinical candidate) stage.
  • The Annual Meeting of AACR is set for April 05 to 10, 2024 at the San Diego Convention Center, California, USA.

St Kitts and Nevis leads the regional agreement on Citizenship by Investment regulations

Retrieved on: 
Monday, March 25, 2024
CBI, Government, Communication, FDI, CIU, Investment, OECS, MOA, Legislation, Memorandum, Organization, Commonwealth

Caribbean CBIPs are designed to obtain foreign direct investments (FDIs) to support socio-economic developments in exchange for citizenship through thorough stringent due diligence processes.

Key Points: 
  • Caribbean CBIPs are designed to obtain foreign direct investments (FDIs) to support socio-economic developments in exchange for citizenship through thorough stringent due diligence processes.
  • The current Charmain of the OECS, Prime Minister of St Kitts and Nevis, Honourable Dr. Terrance Drew, spearheaded this initiative to enhance collaboration among the five Caribbean CBI countries.
  • In this instance, St Kitts and Nevis and Caribbean CBIP countries have collectively adopted CBI legislation that maintains the integrity and security of Caribbean CBIPs.
  • Although ahead of the curve, St Kitts and Nevis introduced new legislation last year addressing many of these areas now reflected in the Memorandum of Agreement, including increasing the investment thresholds.

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Retrieved on: 
Monday, March 25, 2024
AbbVie, Ulcerative colitis, Patient, Inflammation, ABBV, Acquisition, IBD, MOA, Therapy, NLRX1, Calendar, Pharmaceutical industry

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

Key Points: 
  • NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
  • Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
  • “NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn’s disease.
  • The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos’ stockholders.

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Retrieved on: 
Friday, March 22, 2024
Day, Ora, Dry, NCP, Conjunctiva, BID, Physiology, Patient, Pain, Ophthalmology, Observation, Blurred Vision, Doctor of Philosophy, Itch, DED, MOA, Safety, Screen time, Telecanthus, Medical director, FDA, Pharmaceutical industry

Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.

Key Points: 
  • Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.
  • Tear Film Break-up Time showed statistically significant improvement as early as day 15 with the benefit durable for the remainder of the trial.
  • Burning/Stinging, and Blurred Vision improved as early as day 15 and the benefit remained durable throughout the trial.
  • Significant improvements were observed across multiple symptoms as measured in a daily symptom diary including pain, burning/stinging, eye dryness and itching within the first two weeks of treatment.

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Retrieved on: 
Thursday, March 28, 2024
OHE, Week, Cirrhosis, Patient, Mitt, NDA, MOA, File, Stage 2, SMI, Recurrence, FDA

SALT LAKE CITY, March 28, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148.

Key Points: 
  • SALT LAKE CITY, March 28, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148.
  • LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action (MOA).
  • This Phase 2 proof of concept study was a randomized placebo-controlled study in sarcopenic male patients with cirrhosis on the liver transplant waitlist.
  • During Stage 2, 8 participants who were on placebo in Stage 1 converted to LPCN 1148, and 11 participants who started the study on LPCN 1148 continued treatment with LPCN 1148.

Verb Biotics Announces Data from Preclinical Studies to Support Foundational Gut Microbiome Health from Newly Launched Keystone Postbiotic™

Retrieved on: 
Tuesday, March 19, 2024
Health, Antioxidant, Keystone, Powder, Capsule, Probiotic, Butyric acid, Functional food, Overalls, Cytokine, MOA, Drink, Water, Prebiotic (nutrition), Immune system, Caco-2, Vaccine

BOSTON, March 19, 2024 /PRNewswire/ -- Verb Biotics, a microbiome health ingredient company, today announced preliminary preclinical data from their newly launched Keystone Postbiotic™, a foundational gut microbiome solution to help support and strengthen gut microbiome health.

Key Points: 
  • BOSTON, March 19, 2024 /PRNewswire/ -- Verb Biotics, a microbiome health ingredient company, today announced preliminary preclinical data from their newly launched Keystone Postbiotic™, a foundational gut microbiome solution to help support and strengthen gut microbiome health.
  • Verb Biotics has conducted thorough in-vitro and preliminary human studies to understand how Keystone Postbiotics' deliberately chosen active components contribute to maintaining a robust gut microbiome and a well-regulated immune response.
  • The preclinical data contributed to the decision by Verb Biotics to commence human clinical studies in January 2024 to evaluate the potential support of foundational gut microbiome health by Keystone Postbiotic™.
  • Keystone Postbiotic™ combines strains, grains, and botanicals to deliver functional redundancy to support foundational gut microbiome health.

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Thursday, March 7, 2024
Therapy, ARVO, Research, Investment, FDA, Food, Sale, Șaeș, Exercise, Diabetic retinopathy, Safety, Visual acuity, AMD, Patient, Drug, Clinical trial, MOA, Net, Retina, Plasma, Conditional sentence, Angiogenesis, Pharmaceutical industry

ET –

Key Points: 
  • ET –
    WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and highlighted recent corporate developments.
  • “2023 was an exceptional year of execution and results for EyePoint Pharmaceuticals.
  • Review of Results for the Fourth Quarter Ended December 31, 2023
    For the quarter ended December 31, 2023, total net revenue was $14.0 million compared to $10.5 million for the quarter ended December 31, 2022.
  • ET to discuss the results for the fourth quarter and year ended December 31, 2023 and recent corporate developments.

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Retrieved on: 
Wednesday, March 6, 2024
Paper, Combination therapy, Breast cancer, SAN, Woman, FDA, Animal, Proteolysis targeting chimera, Behavior, Therapy, Selective estrogen receptor degrader, Enzyme inhibitor, CNS, Pharmacokinetics, Survival, MOA, Research, Mutant, Pharmaceutical industry

The paper, titled “Palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination”, describes the scientific background underlying the design, discovery and optimization of palazestrant.

Key Points: 
  • The paper, titled “Palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination”, describes the scientific background underlying the design, discovery and optimization of palazestrant.
  • “What’s even more exciting is to see how faithfully the pre-clinical research predicted the behavior of palazestrant now that it is in late-stage clinical development.
  • In mouse xenograft models, palazestrant demonstrated excellent pharmacokinetics, was well tolerated, showed synergy with CDK4/6 inhibitors, and was highly effective at reducing tumor growth in both wild-type and ESR1-mutant ER+ breast cancer.
  • In addition, in an ESR1-mutant intercranial xenograft model, palazestrant inhibited tumor growth and improved survival of animals with CNS metastases, even after stopping drug treatment.

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Neoplasm, Cetuximab, Jefferies Group, Research, Chemistry, Nivolumab, Table, NETS, IRS, NK, Pancreatic cancer, Head, 5T4, DCR, Investigational New Drug, Escape Room, SCCHN, Interim, MD Anderson Cancer Center, Congress, Net, Three Months, International Financial Reporting Standards, CMC, Immune system, International, ESMO, Neutrophil extracellular traps, University, STAT3, AACR, CM24, Conference, Tumor microenvironment, MOA, IND, Insurance, Acquisition, ADS, Drug resistance, Food, Average cost, CEACAM1, PDAC, Administration, Patient, Pharmaceutical industry

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market

Retrieved on: 
Friday, February 23, 2024
Therapy, Rheumatology, Rheumatoid arthritis, Physician, Rituximab, Adalimumab, JAK, Health, Patient, MOA, TNF, Research, Pharmaceutical industry

As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.

Key Points: 
  • As demand for improved outcomes rises, it is vital for manufacturers to understand the top drivers catalyzing switching decisions in the well-established, yet continually evolving, RA landscape.
  • Ongoing research from Spherix Global Insight’s Patient Chart Dynamix™: Rheumatoid Arthritis (US) service, marking its eighth year of tracking the US RA switch market, sheds light on these key treatment trends and leading opportunities for drug manufacturers.
  • While “TNF cycling” remains common, accounting for about one-third of all switches, this trend has been declining since 2017.
  • Brands that excel in these areas are well-positioned to capture market share and reshape treatment approaches.